SotaHEXAL

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of SotaHEXAL

SotaHEXAL is a prescription-only medicinal preparation used for the management and stabilization of abnormal electrical rhythms of the heart, known as arrhythmias. The drug's sole active ingredient is Sotalol hydrochloride (INN), a synthetically derived chemical substance. The preparation is manufactured by HEXAL AG and is primarily supplied for oral administration in the form of a tablet, although Sotalol is also available in liquid forms for specific clinical scenarios.

Property Description
Active ingredient Sotalol hydrochloride
Form Tablet (oral), Oral Solution, Injectable Solution
Pharmacological class Antiarrhythmic (Class II & Class III), Non-selective Beta-Adrenergic Blocker
Common use Management of abnormal heart rhythms
Origin Synthetic (methanesulfonanilide derivative)

What Type of Antiarrhythmic Agent is Sotalol?

Sotalol is uniquely categorized as an antiarrhythmic drug that possesses two key actions, placing it in both the Vaughan Williams Class II and Class III pharmacological groups. This dual classification means Sotalol functions both as a non-selective beta-adrenergic blocker (Class II activity) and exhibits significant potassium channel-blocking properties (Class III activity). This dual action is a differentiating factor for Sotalol, making it clinically recognized for treating complex rhythm disorders where both rate control and rhythm stabilization are necessary.


The General Purpose of SotaHEXAL

The primary purpose of SotaHEXAL is to promote overall stability and efficiency of cardiac function by restoring and maintaining a stable, regular pattern of electrical activity. By combining its ability to slow the heart rate with its capacity to stabilize the heart's electrical recovery period, the medicine works to counteract the chaotic signals typical of an irregular heartbeat, offering a combined benefit distinct from many single-action agents.

Regulatory References

  1. National Institutes of Health

What side effects are possible with SotaHEXAL?

Officially Documented Adverse Reactions and Safety Profile

The safety profile of SotaHEXAL, containing Sotalol hydrochloride, is characterized by adverse effects arising from its dual action as both a beta-adrenergic and potassium channel blocker. The most critical safety consideration explicitly documented in regulatory labeling is the risk of proarrhythmia, which involves the aggravation of existing heart rhythm disturbances or the provocation of a new, potentially life-threatening ventricular rhythm, primarily Torsade de Pointes (TdP). This risk is recognized as dose-dependent and is typically highest within the first seven days of treatment initiation or following a dose increase.

Adverse reactions are formally categorized by frequency, spanning multiple system-organ classes:

Frequency Category Representative Adverse Reactions
Very Common (ge 10%) Fatigue, dizziness, asthenia, nausea, vomiting, sinus bradycardia (slow heart rate).
Common (1% to < 10%) Palpitations, chest pain, dyspnoea (shortness of breath), hypotension (low blood pressure), abdominal pain, diarrhoea, headache, sleep disorder.

Serious adverse reactions listed include Torsade de Pointes and the worsening of cardiac failure. The safety labeling also includes specific constraints for certain populations and clinical contexts. Caution is mandatory for patients with renal impairment (kidney function issues), as drug clearance is reduced, increasing accumulation risk. Additionally, the drug may mask signs of hypoglycemia in patients with diabetes mellitus or the cardiovascular signs of hyperthyroidism. The abrupt withdrawal of therapy in patients with underlying coronary artery disease may exacerbate existing angina or precipitate new cardiac events, a risk associated with the beta-blocker class.

Overdose and Emergency Response

Overdosage with Sotalol hydrochloride, the active ingredient in SotaHEXAL, is classified in regulatory documents as a medical emergency and may be fatal. Immediate medical attention is required for any suspected overdosage due to the high risk of severe, life-threatening events.


Documented Overdose Manifestations

The officially documented clinical signs of overdosage primarily reflect the drug’s effects on heart rhythm and circulation. Expected manifestations include bradycardia (abnormally slow heart rate), severe hypotension (low blood pressure), and prolongation of the QT interval. Other documented presentations are the worsening of congestive heart failure, bronchospasm, and hypoglycemia (low blood sugar). Overdosage has resulted in malignant ventricular arrhythmias, specifically Torsade de Pointes (TdP), cardiac asystole, and death.


Regulatory-Mandated Actions

If overdosage is suspected, SotaHEXAL therapy must be discontinued immediately. The patient requires close observation in a medical setting until the heart rate normalizes to greater than 50 beats per minute and the QT interval resolves. Treatment described in regulatory labeling is symptomatic and supportive. For severe bradycardia or asystole, interventions such as transvenous cardiac pacing or administration of Atropine may be employed. Hemodialysis is documented as a useful measure to reduce the drug's plasma concentration.

Therapeutic Uses of SotaHEXAL

What SotaHEXAL treats: main uses and benefits

SotaHEXAL contains the active substance sotalol hydrochloride, which belongs to a group of medicines known as class III anti-arrhythmics. It is primarily used to manage and prevent certain types of irregular heartbeats, often referred to as cardiac arrhythmias.

Therapeutic indications

This medication is used to control heart rhythm disorders that originate in different chambers of the heart. These include:

  • Ventricular arrhythmias: Serious disturbances in the heart rhythm originating in the lower chambers (ventricles) of the heart.
  • Supraventricular arrhythmias: Irregular heart rhythms originating in the upper chambers of the heart, such as atrial fibrillation or atrial flutter. It is often used to help maintain a normal heart rhythm after a patient has been converted from an irregular rhythm.

How it works

SotaHEXAL works by influencing the electrical activity of the heart muscle. It has a dual mechanism of action:

  1. Beta-blocking effect: It reduces the effects of stress hormones like adrenaline on the heart, which helps to slow the heart rate.
  2. Class III anti-arrhythmic effect: It prolongs the duration of the electrical impulses in the heart muscle cells. This helps to stabilize the heart's rhythm and prevents the heart from beating too fast or irregularly.

Expected benefits

The main goal of treatment with SotaHEXAL is to restore and maintain a stable, regular heartbeat. By controlling the heart's rhythm, the medication helps to reduce the symptoms associated with arrhythmias, such as palpitations, dizziness, and shortness of breath. It is intended to improve the heart's efficiency in pumping blood throughout the body and to reduce the frequency of arrhythmic episodes.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile for SotaHEXAL (Sotalol Hydrochloride)

This section outlines the official eligibility requirements and exclusions for SotaHEXAL, based strictly on government regulatory documents.


Contraindications (Must Not Use)

SotaHEXAL is strictly contraindicated and must not be used by patients with the following conditions:

  • Cardiac Electrical Instability: Existing Long QT Syndromes (congenital or acquired), untreated Sinus Bradycardia (heart rate below 50 beats/minute), or Second- and Third-Degree Atrioventricular (AV) Heart Block (unless a functioning pacemaker is present).
  • Severe Organ Dysfunction: Severe Renal Impairment (Creatinine Clearance typically <10 mL/min) or uncontrolled, severe heart failure (e.g., NYHA Class IV).
  • Respiratory Conditions: Bronchial Asthma or any other related bronchospastic condition.
  • Other Exclusions: Known hypersensitivity to sotalol or sulfonamide derivatives, Cardiogenic Shock, and pre-existing Hypokalemia or Hypomagnesemia until corrected.

Restricted and Conditional Use

  • Renal Impairment: Use is restricted and requires a reduced dosage for patients with moderate renal impairment (Creatinine Clearance 10 to 60 mL/min).
  • Age: The medicine is not established for use in children younger than 2 years of age. Use in older adults requires caution due to potential decreased kidney function.
  • Life Stage: Use during pregnancy is generally not recommended or should be avoided, and breastfeeding is contraindicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of SotaHEXAL primarily through two major risk domains: additive effects on heart rhythm and function, and altered oral absorption.

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Class I and other Class III Antiarrhythmics; other Beta-Blockers; Calcium Channel Blockers (Verapamil, Diltiazem); Catecholamine-Depleting Agents (Reserpine, Guanethidine); Potassium-Depleting Diuretics; QTc Prolonging Agents; Aluminum or Magnesium Hydroxide Antacids.
Mechanistic basis of interactions (only if stated in label) Additive Electrocardiographic Effect (QTc prolongation, Torsade de Pointes risk); Additive Hemodynamic/Conduction Effects (bradycardia, hypotension); Reduced Oral Absorption (lower plasma concentration/exposure). Sotalol is not metabolized by the liver, ruling out significant CYP-mediated interaction.

Official interaction statements:

  • Co-administration with Class I and other Class III antiarrhythmic medicinal products is formally contraindicated due to the severe risk of additive QTc prolongation.
  • Administration of aluminum or magnesium hydroxide antacids must be separated from Sotalol by at least two hours because these substances reduce the drug's oral absorption and overall exposure.
  • Co-administration with Potassium-Depleting Diuretics increases the potential for QTc prolongation and Torsade de Pointes due to the resulting hypokalemia.
  • Concomitant use with other Beta-Blockers or rate-limiting Calcium Channel Blockers increases the risk of marked bradycardia and hypotension due to additive hemodynamic effects.

Connection to the overall interaction profile: Regulatory documents define Sotalol's interaction structure primarily through pharmacodynamic reinforcement of electrical and mechanical cardiac effects, and pharmacokinetic alteration of plasma exposure via absorption. This results in the official classification of multiple medicinal product combinations as contraindicated and imposes specific timing-based separation rules for antacids. The risk of accumulation and associated interaction effects is heightened in patients with documented renal impairment due to Sotalol's primary renal excretion.

Mechanism of Action

SotaHEXAL (sotalol) influences cardiac function through a dual pharmacodynamic mechanism, combining Class II and Class III antiarrhythmic activity.

Modulating Cardiac Electrical Activity via Ion Channels

Sotalol functions as a Class III agent by specifically inhibiting the rapid delayed-rectifier potassium current (IKr) in cardiac tissue. This blockade restricts the efflux of K^+ ions during the repolarization phase, which consequently prolongs the cardiac action potential duration and the effective refractory period (ERP) in both atrial and ventricular tissue. This mechanistic cascade modifies the heart's electrical cycle and governs cardiac excitability.

Attenuating Adrenergic Signaling

The drug simultaneously acts as a non-selective beta-adrenergic receptor antagonist (Class II activity), binding competitively to both beta1- and beta2-receptors. This receptor binding engages pathways that reduce the stimulatory effects of circulating catecholamines, leading to a system-level physiological consequence of decreased heart rate (negative chronotropy) and a reduction in the force of contraction (negative inotropy). This contributes to reduced cardiac activity and diminished myocardial oxygen demand.

Dosage and Administration Information

Official Administration and Dosing Guidelines

SotaHEXAL (Sotalol hydrochloride) is available for both oral administration (tablets or solution) and intravenous (IV) use. The medication's usage is governed by strict protocols to ensure proper dose finding and maintenance.

Standard Labeled Dosing Regimen

Parameter Instruction
Initial Oral Dose 80 mg administered twice daily (BID).
Titration Interval Dose adjustments may be made every 2 to 3 days to allow for the attainment of steady-state plasma concentrations.
Typical Maintenance Most patients respond to a total daily dose of 160 mg to 320 mg, divided into two doses.

Procedural and Contextual Instructions

Administration Timing: Oral doses should be taken 1 to 2 hours before meals, as taking the medicine with food, particularly dairy products, can reduce the absorption of the active ingredient.

Renal Function Adjustment: Because the drug is excreted primarily through the kidneys, the dose or the dosing interval must be adjusted based on creatinine clearance (CrCl) to prevent accumulation. For example, a CrCl between 30 and 59 mL/min often requires extending the dosing interval to 24 hours. No dose adjustment is typically required for hepatic impairment.

Treatment Initiation: The start of therapy or any subsequent dose increase must occur in a facility equipped for continuous electrocardiographic (ECG) monitoring for a minimum of three days.

Missed Dose: If a dose is missed, patients should take the next scheduled dose at the usual time; do not double the dose or shorten the dosing interval to compensate for the missed dose.

Recent Clinical Evidence

Evidence for Use in Severe Ventricular Rhythm Disorders

Research has explored whether SotaHEXAL is relevant in studies involving adults with documented, life-threatening irregularities in the heart's lower chambers, known as sustained ventricular tachyarrhythmias (VTs). These investigations included randomized controlled trials (RCTs) and long-term observational cohort studies. Researchers primarily monitored outcomes related to physical discomfort and systemic or functional imbalance by measuring the rate at which VTs returned and the frequency of electrical shocks delivered by implanted cardioverter-defibrillators (ICDs). Findings from these trials reported measurements of VT recurrence patterns in participants. However, reviews by regulatory bodies and scientific literature noted that the available evidence did not demonstrate an enhancement of overall survival rates in these patient groups.

Evidence for Maintaining Normal Heart Rhythm (Atrial Fibrillation/Flutter)

The research base includes numerous controlled trials and large systematic reviews that explored SotaHEXAL in the context of Atrial Fibrillation (AFIB) and Atrial Flutter. These studies primarily focused on adults with symptomatic AFIB/AFL who had recently had their heart rhythm restored. Research examined the medicine's role in studies that measured the time elapsed before the return of the irregular heart rhythm. Findings from trials reported observations on the time interval between treatment initiation and the first measured recurrence. However, high-certainty meta-analyses described a pattern where the use of the drug was associated with higher all-cause mortality in some studied populations compared with placebo or no treatment.

Key Research Gaps and Uncertainties

Research highlights what is known—and what is still uncertain—about SotaHEXAL. One key limitation is the absence of evidence demonstrating that the drug enhances long-term survival in patients with life-threatening ventricular arrhythmias. Furthermore, high-certainty evidence for Atrial Fibrillation has documented an association with higher all-cause mortality in specific study populations. The evidence quality for preventing arrhythmias after cardiac surgery is characterized by short-term follow-up durations. Research in special groups, such as children, or patients with multiple conditions, is also limited, with data for certain subgroups remaining insufficient.

Frequently Asked Questions (FAQ)

Common questions about SotaHEXAL (FAQ)


Q: What is the difference between SotaHEXAL and other common heart medications?

A: SotaHEXAL's active ingredient, sotalol, is unique because it combines two distinct actions. The l-sotalol component works like a beta-blocker (Class II), which can slow the heart rate. At the same time, both parts of the substance contribute to its heart rhythm stabilizing effects (Class III). This combination of actions is a differentiating factor from other agents that may only have one of these effects.


Q: Is there a list of over-the-counter cold medicines to avoid while on SotaHEXAL?

A: Official documents indicate that caution is needed with some over-the-counter cold medicines. Products containing ingredients known as adrenergic agonists—which can include substances like ephedrine—may interact negatively with the beta-blocking action of SotaHEXAL. Official guidance emphasizes that patients should consult a healthcare professional before using cold medicines.


Q: Is SotaHEXAL ever prescribed to children or teenagers?

A: Official product information states that SotaHEXAL is not established for use in children younger than two years of age. For children aged two years and older, the use and specific dosage must be carefully determined by a specialist based on the child's body weight.


Q: Is SotaHEXAL appropriate for elderly patients (over 70)?

A: The official labeling indicates that SotaHEXAL can be used in older adults, but it requires caution. This is primarily because kidney function often decreases with age. Since the drug is cleared through the kidneys, the official guidance emphasizes that dosage may need adjustment due to changes in kidney clearance.


Q: Why do official documents emphasize blood potassium levels when taking SotaHEXAL?

A: Official documents emphasize the importance of maintaining proper blood potassium and magnesium levels because low levels are a significant risk factor. Hypokalemia (low potassium) or hypomagnesemia can increase the potential for a severe, life-threatening heart rhythm disorder called Torsade de Pointes. For this reason, it is critical that any low electrolyte levels are medically managed and corrected prior to initiation.


Q: Do you need to have regular blood tests while taking SotaHEXAL?

A: Official guidelines often recommend routine laboratory checks while taking this medication. These typically include monitoring serum electrolytes, such as potassium and magnesium, as well as checking kidney function. For stable patients, follow-up monitoring of these parameters is typically part of the recommended care plan.


Q: Are there any specific lifestyle changes recommended when using SotaHEXAL?

A: Regulatory information specifically advises caution regarding alcohol consumption while taking SotaHEXAL. Alcohol may cause an additive effect, leading to a greater reduction in blood pressure. This could increase the likelihood of experiencing symptoms such as dizziness or fainting.


Q: What is the purpose of the initial observation period when starting SotaHEXAL?

A: The required initial observation period is mandated to protect against a potentially life-threatening side effect called proarrhythmia. This involves continuously monitoring the heart's electrical activity (ECG) for several days in a clinical setting. The monitoring is required to allow for immediate detection and management of serious irregular rhythms like Torsade de Pointes.


Q: What is the shelf life of SotaHEXAL tablets?

A: According to the official Summary of Product Characteristics, the typical shelf life for SotaHEXAL tablets is 36 months. Official guidelines require that the medication be stored according to packaging instructions, and it must not be used past its expiration date.


Q: Are there different strengths of SotaHEXAL available?

A: Yes, SotaHEXAL tablets are supplied in various strengths to accommodate different prescribing needs. Common available strengths can include 80 mg, 120 mg, 160 mg, and 240 mg tablets, though the exact options may vary by country or brand.


Q: How quickly should someone expect SotaHEXAL to start working?

A: Based on clinical experience, SotaHEXAL can begin to affect the heart rate and rhythm soon after the first dose is taken. However, the full effect of the medicine is achieved gradually as the concentration stabilizes in the body. Some common temporary effects, such as dizziness or a slower heart rate, may be noticeable early in treatment.


Q: What does it feel like when SotaHEXAL is taking effect?

A: As SotaHEXAL begins to work, some patients may report feeling certain general effects. Common feelings include dizziness, excessive tiredness, weakness, or lightheadedness. These effects are usually related to the medicine's dual action and are documented in the official safety information.


Q: How long does the effect of one dose of SotaHEXAL last?

A: The effects of SotaHEXAL are sustained throughout the day due to its long half-life, which is approximately 12 hours in adults. This means the drug takes several days to reach a stable, or 'steady-state,' level in the blood. This profile helps explain why the medicine is typically prescribed for scheduled administration throughout the day.


Q: Does SotaHEXAL cause weight gain?

A: Official adverse reaction lists do not categorize weight gain as a common side effect of SotaHEXAL. However, the patient information emphasizes that any sudden or unexpected weight gain, particularly gaining multiple pounds in a single day, should be reported to a healthcare professional immediately. Weight gain should be reported immediately, as it may be a physical manifestation of a worsening underlying heart condition.


Q: What is the difference between the 'D' and 'L' forms of the active substance in SotaHEXAL?

A: The active ingredient, sotalol, is a racemic mixture, meaning it is composed of two chemical forms known as d- and l-isomers. Regulatory documents clarify that the l-isomer performs nearly all of the beta-blocking (Class II) action, which slows the heart. However, both the d- and l-isomers are equally responsible for the antiarrhythmic (Class III) action, which stabilizes the heart rhythm.


Q: Does SotaHEXAL interact with common pain relievers like ibuprofen?

A: Official interaction checkers indicate that common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen may reduce the effectiveness of SotaHEXAL. Specifically, this combination may lessen the blood pressure-lowering effects of the medication. Official interaction warnings state that using NSAIDs may necessitate increased monitoring.


Q: Are there specific vitamins or supplements that are known to interact with SotaHEXAL?

A: Regulatory information indicates that SotaHEXAL should be taken at least two hours apart from multivitamins that contain minerals. This timing separation is necessary because the minerals can prevent the body from absorbing enough of the medication. Furthermore, insufficient data is available to confirm the safety profile of combining SotaHEXAL with most herbal remedies.


Q: What are the signs of taking too much SotaHEXAL?

A: The official patient information describes several signs that may indicate an overdose of SotaHEXAL. These symptoms can include an irregular, excessively fast, or excessively slow heartbeat, fainting, or trouble breathing. Other possible signs are swelling in the limbs and severe dizziness or extreme fatigue.


Q: Does SotaHEXAL have a Black Box Warning in the US?

A: Yes, the US Prescribing Information for sotalol includes a Boxed Warning, which is the strongest warning the FDA requires. This warning highlights the significant, life-threatening risk of developing proarrhythmia, which involves the heart rhythm becoming dangerously irregular. This risk is specifically related to QTc interval prolongation.


Q: Is SotaHEXAL known to interfere with driving or operating machinery?

A: Official patient counseling advice addresses activities like driving and operating machinery. Because common side effects include feelings of tiredness and dizziness, official safety guidance advises that patients should not drive or operate heavy machinery until they are certain how the medicine affects them.


Q: Can SotaHEXAL interact with alcohol consumption?

A: Regulatory documents caution that consuming alcohol while taking SotaHEXAL may lead to an additive effect on blood pressure. This combination can intensify the blood pressure-lowering effects, potentially increasing the risk of symptoms such as dizziness, lightheadedness, or fainting.


Q: What is the typical time frame for follow-up appointments when taking SotaHEXAL?

A: After the initial period of therapy initiation, regulatory guidelines recommend ongoing monitoring for stable patients. This typically involves checking the heart's electrical activity (ECG) every six to twelve months. Additionally, lab work to check electrolytes and kidney function is frequently recommended every six months.


Q: Can SotaHEXAL be split or crushed for easier swallowing?

A: Clinical information advises against splitting or crushing SotaHEXAL tablets. This is due to the drug's narrow therapeutic window and the significant risk associated with life-threatening arrhythmias if the dose is altered or inconsistent. Patients who have difficulty swallowing should discuss alternative options, such as liquid formulations or adjusting the prescription strength, with their healthcare provider.

How should SotaHEXAL be stored and disposed of?

Storage and Disposal of SotaHEXAL (Sotalol Hydrochloride)

Official regulatory documents define strict conditions for the storage of SotaHEXAL to maintain its quality and labeled stability. The medicine must be stored at a temperature below 25 C and should be protected from light, heat, and moisture.

Storage Requirements

Condition Requirement
Temperature Store below 25 C.
Protection Store in the original package to protect from light.
Safety Keep out of the sight and reach of children.
Stability Do not use the product past the expiry date printed on the carton.

Disposal Instructions

Any unused or expired SotaHEXAL must be disposed of in accordance with local requirements for pharmaceutical waste. Regulatory guidelines prohibit discarding the medicine via wastewater or household waste. A pharmacist can provide information on proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of SotaHEXAL found in:

A-Z Index: